2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2219

Remaining Pain in DMARD-Naive Rheumatoid Arthritis Patients Treated with Baricitinib and Methotrexate
Abstract Number: 2220

Neuropathic-like Pain Affects the Tender Joint Count and Health-Related Quality of Life in Patients with Rheumatoid Arthritis
Abstract Number: 2221

Eradication of Hepatitis C Among US Veterans: Examination of Changes in Pain Severity and Prescription Opioid Use Following Treatment
Abstract Number: 2222

Comparative Risk of Respiratory Depression in Patients Treated with Opioids for Non-Malignant Pain
Abstract Number: 2223

Reallocating Time Spent in Sleep, Sedentary Behavior and Physical Activity and Its Association with Pain and Depression
Abstract Number: 2224

Analgesic Potential of NEO6860, a Modality Selective TRPV1 Antagonist, in Osteoarthritis Knee Pain: Results of a Randomized, Controlled, Proof-of-Concept Trial
Abstract Number: 2225

Cntx-4975 (Trans-Capsaicin) Injection Provides Clinically Meaningful Pain Reduction in Subjects with Painful Intermetatarsal Neuroma (Morton’s Neuroma): An Open-Label, Ascending-Dose Study
Abstract Number: 2226

Cntx-4975 (Trans-Capsaicin) Injection Provides Clinically Meaningful Pain Reduction in Subjects with Painful Intermetatarsal Neuroma (Morton’s Neuroma): A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study
Abstract Number: 2227

S100A9 Induces a Pain Response during Experimentally Induced Acute Synovitis
Abstract Number: 2228

Involvement of Receptor Tyrosine Kinase a Signaling in Rhumatoid Arthritis Using Trka/C Knock-in Mice: A Multimodal Approach
Abstract Number: 2229

The Effect of Intra-Articular Neurotoxin on Arthritis Pain and Substance P Expression in the Dorsal Root Ganglion: Results from Murine Arthritis Models
Abstract Number: 2230

Use of Prescription Opioids Among Patients with Systemic Inflammatory Diseases (SID) Versus Patients with Hypertension but No Sid
Abstract Number: 2231

MCC22, a Novel Compound That Targets Both CCR5 and Mu Opioid Receptors, Is Highly Effective in Treating Inflammatory Arthritis Pain
Abstract Number: 2232

A Role for CCR2 in Chronic Behavioral and Neuroimmune Changes in the DMM Model of Osteoarthritis
Abstract Number: 2233

The Role of Life Purpose in Disability and Depression in Patients with Acute Low Back Pain

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].